Background: Ranked 5th in domestic market with Net Sales of INR 69.6bn with 230 brands. R&D; - 8% of Sales. Chronic,semi-chronic therapies account for 54%. FY07 - FY 12: Sales CAGR - 27%, PAT CAGR - 25%. Vertically integrated with strengths in manufacturing and IP based products.12 Mfg sites of which 2 in Japan. API sites -5, Formulation sites -7. 5 FDA inspected sites. Exports account for 70% of sales with US-38%, ROW-17%, Japan-12%, Europe-3%. Formulations- 90% of...